Marinus Pharmaceuticals (MRNS) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Air Ecological Environment Environmental Extreme Weather Intensity Life Cycle Materials Natural Resources Nature Offset Package Packaging Pandemic Raw Materials Regenerative Water Access African American Asian Benefits Black California Consumer Privacy Act Charitable Collective Bargaining Community Culture Customer Cyber Cybersecurity Data Privacy Data Security Death Demographic Demographics Disability Diversity Drug Pricing Employee Employee Engagement Engagement Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Labor Standards LGBTQ Opioid Perquisites Privacy Product Quality Product Safety Recall Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workforce Action Plan Assessment Assurance Attorney General Attorneys General Audit Board Oversight Bonus Bribery Chronic Class Action Lawsuit Classified Classified Board Clawback Commitment Conflict of Interest Corporate Governance Corporate Social Responsibility Corruption Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Plaintiff Pledging Poison Pill Procurement Purpose R&D Recoup Reputation Reputational Research and Development Responsibility Responsible Self-evaluation Special Meeting Stockholder Engagement Stockholder Outreach Strategy Sustainability Sustainable Targets Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 26, 2021, Marinus Pharmaceuticals, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 36,633,490 shares of common stock outstanding and entitled to vote at the Annual Meeting, 26,891,520 shares, or 73.4% were present, either by remote communication or represented by proxy, constituting a quorum. The following provides a summary of the votes cast for the proposals on which the Company’s stockholders voted at the Annual Meeting:

Proposal 1: Election of three Class I directors to the Company’s Board of Directors (our “Board”), each to serve until the Company’s 2024 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.

The Company’s stockholders elected the following individuals to serve as Class I directors to serve until the Company’s 2024 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified, and the results of the vote were as follows:

Director Nominee
Charles Austin	22,978,483	379,905	3,533,132
Michael R. Dougherty	23,014,914	343,474	3,533,132
Elan Ezickson	18,258,810	5,099,578	3.533,132

Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021.

The Company’s stockholders approved Proposal 2. The results of the vote were as follows:

For				Against				Abstain				Broker Non-Votes
	26,857,174				16,056				18,290				-

Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting.

The Company’s stockholders approved Proposal 3. The results of the vote were as follows:

For				Against				Abstain				Broker Non-Votes
	17,644,671				5,675,192				38,525				3,533,132